Representative before the EPO

Employment test 11 - 50 employees
Company dna eip1
operating since 2009
Headquarter in London and 4 offices
active in Legal Services and IP Consulting

Andrew John Sharples has worked on the following 18 EPO patent applications which have been published in the last five years:

EP11734227

STATIN THERAPY MONITORED BY GALECTIN- 3 MEASUREMENT

IPC classification:
A61K 31/505, A61P 9/00, G01N 33/50
Agent:
Andrew John Sharples, EIP Europe LLP
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP12783456

RESTRICTED IMMUNOGLOBULIN HEAVY CHAIN MICE

IPC classification:
A01K 67/027, C07K 16/46, C12N 15/85
Applicant:
Regeneron Pharmaceuticals Inc
Agent:
Andrew John Sharples, EIP Europe LLP
Status:
The patent has been granted
EP11835162

CHLAMYDIA ANTIGENS AND USES THEREOF

IPC classification:
A61K 39/118
Agent:
Andrew John Sharples, EIP Europe LLP
Status:
EXAMINATION IN PROGRESS
EP12736908

VACCINES AND COMPOSITIONS AGAINST STREPTOCOCCUS PNEUMONIAE

IPC classification:
A61K 38/00, A61K 39/09
Applicant:
Children's Medical Center Corporation
Agent:
Andrew John Sharples, EIP Europe LLP
Status:
EXAMINATION IN PROGRESS
EP11787442

MULTIVALENT SYNTHETIC NANOCARRIER VACCINES

IPC classification:
A61K 9/51, A61K 31/4745, A61K 31/7115, A61K 33/06, A61K 39/00, A61K 39/385, A61K 39/39, A61K 45/06, A61K 47/02, A61K 47/22, A61K 47/24, A61K 47/48, A61P 25/34, A61P 31/04, A61P 31/10, A61P 31/12, A61P 35/00, A61P 37/04
Applicant:
Selecta Biosciences Inc
Agent:
Andrew John Sharples, EIP Europe LLP
Status:
GRANT OF PATENT INTENDED
EP11787447

DOSE SELECTION OF ADJUVANTED SYNTHETIC NANOCARRIERS

IPC classification:
A61K 9/51, A61K 31/4745, A61K 31/7115, A61K 33/06, A61K 39/00, A61K 39/385, A61K 39/39, A61K 45/06, A61K 47/02, A61K 47/22, A61K 47/24, A61K 47/48, A61P 25/34, A61P 31/04, A61P 31/10, A61P 31/12, A61P 35/00, A61P 37/04
Applicant:
Selecta Biosciences Inc
Agent:
Andrew John Sharples, EIP Europe LLP
Status:
EXAMINATION IN PROGRESS
EP12718709

PYRROLIDINE DERIVATIVES AS SELECTIVE GLYCOSIDASE INHIBITORS AND USES THEREOF

IPC classification:
A61K 31/40, A61K 31/401, A61P 9/10, A61P 11/06, A61P 25/28, A61P 37/00, C07D 207/12, C07D 207/16
Agent:
Andrew John Sharples, EIP Europe LLP
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP12716750

METHODS FOR PREPARATION OF MACROCYCLIC POLYESTER OLIGOMER VIA HETEROGENEOUS CATALYSIS

IPC classification:
B01J 21/06, B01J 21/08, B01J 37/02, C08G 63/183, C08G 63/81, C08G 63/85
Agent:
Andrew John Sharples, EIP Europe LLP
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP13746382

COLD BLOCK WITH EMBEDDED CHAMBERED BEVERAGE TAP

IPC classification:
B67D 1/04
Agent:
Andrew John Sharples, EIP Europe LLP
Status:
GRANT OF PATENT INTENDED
EP11787434

NANOCARRIER COMPOSITIONS WITH UNCOUPLED ADJUVANT

IPC classification:
A61K 9/51, A61K 31/4745, A61K 31/7115, A61K 33/06, A61K 39/00, A61K 39/385, A61K 39/39, A61K 45/00, A61K 45/06, A61K 47/00, A61K 47/02, A61K 47/22, A61K 47/24, A61K 47/48
Applicant:
Selecta Biosciences Inc
Agent:
Andrew John Sharples, EIP Europe LLP
Status:
EXAMINATION IN PROGRESS
EP12795905

HUMANIZED IL-6 AND IL-6 RECEPTOR

IPC classification:
A01K 67/027, C07K 14/54, C07K 14/715
Applicant:
Regeneron Pharmaceuticals Inc
Agent:
Andrew John Sharples, EIP Europe LLP
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP12178807

Herbal therapy for the treatment of food allergy

IPC classification:
A61K 36/074, A61K 36/185, A61K 36/232, A61K 36/258, A61K 36/54, A61K 36/718, A61K 36/736, A61K 36/756, A61K 36/758, A61K 36/9068, A61P 37/08
Agent:
Deborah Mary Hart, Kilburn & Strode LLP
Agent:
Andrew John Sharples, EIP Europe LLP
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP11728027

COMPOUNDS FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE ASSOCIATED DISEASE

IPC classification:
A61K 31/4164, A61K 31/424, A61K 31/4365, A61K 31/437, A61K 31/4439, A61K 31/546, A61K 31/74, A61K 35/741, A61K 35/747, A61K 36/064, A61K 38/14, A61K 39/395, A61K 45/06, A61P 31/04
Agent:
Andrew John Sharples, EIP Europe LLP
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP11838881

MODIFIED NICOTINIC COMPOUNDS AND RELATED METHODS

IPC classification:
A01N 43/40, A61K 31/44, A61K 39/00, A61K 39/385, A61K 47/48
Applicant:
Selecta Biosciences Inc
Agent:
Andrew John Sharples, EIP Europe LLP
Status:
EXAMINATION REQUESTED
EP11715092

BALANCED MYRISTATE- AND LAURATE-CONTAINING EDIBLE OIL

IPC classification:
A23D 7/00, A23D 9/00, A23L 1/29, A23L 1/30
Applicant:
Brandeis University
Agent:
Andrew John Sharples, EIP Europe LLP
Agent:
Høiberg A/S
Status:
PATENT GRANTED
EP12193602

Cell carrier and cell carrier containment devices containing regenerative cells

IPC classification:
A61K 35/28, A61K 35/32
Agent:
Zacco Denmark A/S
Agent:
Andrew John Sharples, EIP Europe LLP
Status:
PATENT GRANTED
EP11842681

LATERAL FLOW IMMUNOASSAY FOR COMPLEMENT ACTIVATION AND METHODS OF USE FOR POINT-OF-CARE ASSESSMENT OF COMPLEMENT-ASSOCIATED DISORDERS

IPC classification:
G01N 33/558, G01N 33/86
Agent:
Andrew John Sharples, EIP Europe LLP
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP12704188

USE OF GALECTIN-3 FOR DETECTING AND PROGNOSING HEART FAILURE AFTER ACUTE CORONARY SYNDROME

IPC classification:
G01N 33/566, G01N 33/68
Agent:
Andrew John Sharples, EIP Europe LLP
Status:
APPLICATION DEEMED TO BE WITHDRAWN

Please Sign in to use this feature